Form 4: Corcept Therapeutics Executive Stock Purchase
Statement of Changes in Beneficial Ownership
Chief Development Officer William Guyer acquired 1,754 shares of Corcept Therapeutics common stock through an incentive plan.
Summary
- William Guyer, Chief Development Officer of Corcept Therapeutics, acquired 877 shares of common stock at $70.44 per share.
- An additional 877 shares were acquired as unvested restricted stock awards at no cost.
- The total beneficial ownership following these transactions is 3,985 shares.
- The transactions were executed on June 1, 2026, under the company's 2024 Incentive Award Plan.
Sentiment
Score: 6
Explanation: StockSavvy.ai views this as a neutral-to-positive event, as it reflects standard executive participation in an established incentive plan rather than a significant market-moving event.
Positives
- Insider acquisition of company stock demonstrates alignment between executive interests and shareholder value.
- Participation in the 2024 Incentive Award Plan suggests confidence in the company's long-term development trajectory.
Negatives
- None identified in this filing.
Risks
- Vesting of restricted stock awards is contingent upon the reporting person remaining the beneficial owner of the purchased shares through the one-year anniversary of the grant date.
Future Outlook
The filing does not provide forward-looking financial guidance, focusing solely on the reporting of insider equity transactions.
Industry Context
StockSavvy.ai notes that insider buying in the biotechnology sector is often viewed as a positive signal regarding internal confidence in clinical development pipelines and regulatory progress.
Comparison to Industry Standards
- The use of incentive award plans for executive stock acquisition is standard practice among mid-cap biotechnology firms to ensure management retention and alignment.
- The transaction structure follows typical SEC reporting requirements for Section 16 officers.
Stakeholder Impact
- Shareholders may interpret the executive's investment as a sign of confidence in the company's future performance.
Next Steps
- Vesting of restricted stock awards on the one-year anniversary of their respective grant dates.
Key Dates
| Date | Description |
|---|---|
| 2025-12-01 | Grant date for initial unvested restricted stock awards. |
| 2026-03-02 | Grant date for subsequent unvested restricted stock awards. |
| 2026-06-01 | Transaction date for the purchase of common stock and grant of restricted stock awards. |
| 2026-06-03 | Filing date of the Form 4. |
Keywords
Corcept Therapeutics, CORT, Insider Trading, Form 4, Executive Compensation, Biotech
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.